OncoMatch/Clinical Trials/NCT06549595

A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

Is NCT06549595 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Surovatamig and R-CHOP for untreated follicular lymphoma.

Phase 3RecruitingAstraZenecaNCT06549595Data as of May 2026

Treatment: Surovatamig · R-CHOP · R-CVP · BR — This is a global, randomised, Phase III, multicentre, open-label study evaluating the efficacy, safety and the degree of added benefit of the Surovatamig (AZD0486) plus rituximab combination compared to Investigator's choice of 3 standard immunochemotherapy regimen, conducted in participants with untreated FL.

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Hodgkin Lymphoma

Disease stage

Required: Stage II, III, IV

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Lab requirements

Blood counts

adequate hematological function

Kidney function

adequate renal function

Liver function

adequate liver function

Cardiac function

adequate cardiac function

Adequate liver, hematological, renal and cardiac function.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

Research Site · Anchorage, Alaska
Research Site · Aurora, Colorado
Research Site · New Haven, Connecticut
Research Site · Ann Arbor, Michigan
Research Site · New York, New York

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify